Stereotaxis (NYSEAMERICAN:STXS) Announces Quarterly Earnings Results

Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05), FiscalAI reports. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $8.35 million. Stereotaxis had a negative net margin of 74.24% and a negative return on equity of 133.35%.

Here are the key takeaways from Stereotaxis’ conference call:

Get Stereotaxis alerts:

• Recurring revenue reached $6.2 million in Q2, driven by the launch of MAGiC and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to rise to approximately $7 million in Q3 and $8 million in Q4.
• MAGiC adoption is expanding, with roughly a dozen U.S. hospitals approved to purchase the catheter and procedure-level disposable revenue generally in the $5,000–$8,000-plus range. Demand currently exceeds supply, but the company expects about $1 million of incremental catheter revenue in each of the next two quarters as manufacturing ramps.
• Stereotaxis received its first U.S. GenesisX order and expects installation this fall alongside a non-modified X-ray, supporting formal compatibility with that manufacturer. Synchrony also generated initial orders and is expected to contribute more than $1 million of system revenue per quarter in the near term.
• Q2 revenue was $7.7 million, down year over year because no robotic system was delivered, while the company posted a $4.5 million net loss and $3.7 million of negative free cash flow. Gross margins remained pressured by low manufacturing volumes, and management acknowledged ongoing adoption barriers including catheter supply, GenesisX validation, and X-ray compatibility.
• Management reiterated its expectation of reaching cash-flow profitability in the first half of 2027 without additional financing, assuming continued catheter adoption and modest system sales. The company also highlighted longer-term growth opportunities from a wireless/mobile robot, pulse-field-ablation catheters, AI-enabled surgery, and the recently completed Robocath acquisition.

Stereotaxis Stock Performance

STXS stock opened at $1.40 on Thursday. The company has a market capitalization of $137.10 million, a P/E ratio of -5.83 and a beta of 1.37. The company has a fifty day moving average price of $1.62 and a 200-day moving average price of $1.86. Stereotaxis has a 52-week low of $1.24 and a 52-week high of $3.59.

Institutional Trading of Stereotaxis

Institutional investors and hedge funds have recently bought and sold shares of the stock. WealthPLAN Partners LLC acquired a new position in Stereotaxis during the 4th quarter worth about $29,000. BNP Paribas Financial Markets raised its holdings in Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after purchasing an additional 5,910 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Stereotaxis during the third quarter worth $38,000. HRT Financial LP acquired a new position in shares of Stereotaxis in the 4th quarter valued at about $42,000. Finally, Moneta Group Investment Advisors LLC bought a new position in shares of Stereotaxis during the 3rd quarter worth approximately $43,000. 45.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on STXS. Citigroup reiterated a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday, June 3rd. TD Cowen lowered their price target on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $3.50 price objective (down from $4.00) on shares of Stereotaxis in a report on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $3.70.

Check Out Our Latest Report on Stereotaxis

About Stereotaxis

(Get Free Report)

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.

Featured Stories

• Five stocks we like better than Stereotaxis
• Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
• Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?

Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.